Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,951 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, Lamb D, McClure B. Rischin D, et al. Among authors: fisher r. J Clin Oncol. 2005 Jan 1;23(1):79-87. doi: 10.1200/JCO.2005.01.072. J Clin Oncol. 2005. PMID: 15625362 Clinical Trial.
Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.
Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, Peters LJ; Trans-Tasman Radiation Oncology Group Study 98.02. Rischin D, et al. Among authors: fisher r. J Clin Oncol. 2006 May 1;24(13):2098-104. doi: 10.1200/JCO.2005.05.2878. J Clin Oncol. 2006. PMID: 16648512 Clinical Trial.
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L. Rischin D, et al. Among authors: fisher r. J Clin Oncol. 2010 Jun 20;28(18):2989-95. doi: 10.1200/JCO.2009.27.4449. Epub 2010 May 17. J Clin Oncol. 2010. PMID: 20479425 Clinical Trial.
Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.
Lim AM, Rischin D, Fisher R, Cao H, Kwok K, Truong D, McArthur GA, Young RJ, Giaccia A, Peters L, Le QT. Lim AM, et al. Among authors: fisher r. Clin Cancer Res. 2012 Jan 1;18(1):301-7. doi: 10.1158/1078-0432.CCR-11-2295. Epub 2011 Nov 17. Clin Cancer Res. 2012. PMID: 22096023 Free PMC article. Clinical Trial.
Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer.
Trinkaus ME, Hicks RJ, Young RJ, Peters LJ, Solomon B, Bressel M, Corry J, Fisher R, Binns D, McArthur GA, Rischin D. Trinkaus ME, et al. Among authors: fisher r. J Med Imaging Radiat Oncol. 2014 Feb;58(1):89-97. doi: 10.1111/1754-9485.12155. J Med Imaging Radiat Oncol. 2014. PMID: 24529061 Clinical Trial.
3,951 results